oral+semaglutide+approval Novo Nordisk's weight-loss pill wins FDA approval US FDA accepts Novo Nordisk's

Assessing the presence of eating disorders in patients seeking treatment for obesity The high prevalence of eating disorders among patients seeking treatment for obesity highlights the need for thorough screening in this population

After two months, the liraglutide group had an average weight loss of 7.5%, compared to 4.0% in the placebo group

It also significantly improved cardiometabolic parameters, including blood pressure, HbA1c, lipids, and C-reactive protein

By choosing a platform that prioritizes these clinical partnerships, you are choosing a higher level of oversight for your health

The boxed-warning row is important and asymmetric: because tirzepatide is approved, its rodent thyroid C-cell finding is formally carried on the label as a warning, whereas CagriSema simply has no label yet